Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection

The void in the literature is that while multimodal pain management reduces postoperative pain in the majority of TKA patients6-14, too many are still dissatisfied with overall pain control13 and adverse drug reactions (dizziness and somnolence) to neuroleptic medications15. Additionally, postoperative falls are greater with femoral nerve blocks16, and new neurological symptoms are associated with the block17. Bupivacaine liposome suspension periarticular injection has large scale national anecdotal support for TKA pain control with avoidance of regional block adversity. There is one recent randomized control trial in TKA patients favorably comparing periarticular injection with bupivacaine liposome suspension versus bupivacaine hydrochloride (HCL)5. To date the clinical use and published evidence most robustly supports bupivacaine liposome suspension in patients undergoing bunionectomy or hemorrhoidectomy. Additionally, in preparation for shorter hospital stays for total joint arthroplasty, a more effective and better tolerated pain management solution is needed.

Hypothesis Statement:

Hospitalized TKA patients without a pre-operative femoral nerve block will experience improved postoperative pain control and less MSO4 equivalence consumption when receiving an injection of bupivacaine liposome suspension versus concentrated multi drug.

Inclusion criteria

• TKA candidacy
• Osteoarthritis
• Failure of non-operative treatments to control knee pain
• Patients able to understand and agree to study inclusion

Exclusion criteria

• Subjects have orthopaedic and medical co-morbidities that would thwart postoperative pain control such as extra-articular pathology with referred pain to the knee (spinal stenosis, neuropathy,ipsilateral hip disease)
• Severe knee deformity
• Post-traumatic and inflammatory arthritis
• BMI above 40
• Patients unable to receive multimodal pain remitting agents
• Active knee sepsis
• Remote sites of active infection
• Diabetes with A1C > 7
• ASA class > lll
• Cardiac disease failing medical clearance
• Severe liver disease
• PAD with AAI < 0.75
• Seizure disorder
• Allergic to any pain remitting agent
• Alcohol abuse
• Smoking abuse